Safety of Use of Pandora for Patients Suffering From Gonarthrosis (PANDORA1)

June 20, 2023 updated by: Labrha

Prospective, Multicenter, Open Study Evaluating the Short-term Safety of Use of Pandora Administered in the Form of 1 Intra-articular Injection of Happyone or 3 Intra-articular Injections of Happysoft in Patients Suffering From Gonarthrosis

The knee osteoarthritis is a frequent degenerative condition that mainly affects subjects over 60, population often weakened by numerous comorbidities and concomitant treatments, justifying the development of new therapies.

The viscosupplementation is a symptomatic treatment for knee osteoarthritis ; the objective of this intra-articular injection of hyaluronic acid is to reduce knee pain and improve mobility. In practice, there are two protocols to administer viscosupplementation : in a single injection or in three injections performed weekly.

The present clinical investigation has the objective to evaluate the safety of use of Pandora in a single injection or in three injections performed weekly.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This clinical investigation is a multicenter, prospective, open study of a class III Medical Device.

This study is designed to evaluate the safety of use of Pandora in its two forms : in a single injection or in three injections.

A descriptive analysis will be carried out to characterize the demographic data, the history of the disease and its treatments, the clinical and radiological data of the patients at inclusion.

The security of use of Pandora will be demonstrated by describing the proportion of patients with at least one adverse event attributable to the treatment, occurring during the week following each injection.

In total, 20 participants will be enrolled across two study centers in France, 10 participants in each centers.

The total duration of subjects participation is 6 months ; overall study duration including the enrollment period is expected to take approximately 9 months.

Study Type

Interventional

Enrollment (Actual)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Belfort, France
        • Hôpital Nord Franche-Comté, HNFC
      • Mulhouse, France
        • Groupe Hospitalier de la Région Mulhouse Sud-Alsace, GHRMSA

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

35 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Twenty patients having a gonarthrosis asserted radiologically and justifying according to the opinion of the rheumatologist a viscosupplementation.

Inclusion Criteria:

  • Patient aged between 35 and 85 years.
  • Body mass index (BMI) < 30 kg.m^2.
  • Medial or lateral femoro-tibial knee osteoarthritis, diagnosed according to the American College of Rheumatology criteria, radiological stage 2 and 3 according to the Kellgren-Lawrence criteria modified by Felson on an X-ray, of the knee in extension, less than 12 months old.
  • Knee osteoarthritis responsible for walking pain in the target knee, assessed between 4 and 8 inclusive on an 11 points numerical scale (0 = none to 10 = extreme).
  • Ambulatory patient able to walk 50 meters without a cane, crutch or walker.
  • Patient able to read, understand, sign and date the patient information sheet.
  • Patient agreeing to follow-up study visits.
  • Patient affiliated to the health social security system.
  • Patient requiring viscosupplementation according to the investigator.

Exclusion Criteria:

  • Patient presenting knee osteoarthritis without impingement joint space narrowing of the femoro-tibial compartment (modified Kellgren stage 0-1) or with complete impingement joint space narrowing on the knee weight-bearing radiograph in extension (modified Kellgren stage 4).
  • Walking pain in the target knee, rated less than 4 or more than 8 on an 11-point numerical scale (0 = none to 10 = extreme).
  • Patient with a flare of osteoarthritis of the target or contralateral knee attested by KOFUS criteria ≥ 7.
  • Patient who received viscosupplementation or Platelet Rich Plasma (PRP) injection in the 6 months prior to inclusion.
  • Patient who received an intra-articular injection of corticosteroids in the target knee in the 2 months prior to inclusion.
  • Patients with a skin condition or a wound next to or near the injection site.
  • Patients refusing to discontinue treatment with NSAIDs or cox-2 inhibitors during the follow-up period.
  • Patient receiving treatment with level III analgesics (strong opioids).
  • Patients receiving treatment with diacerhein, avocado and soy unsaponifiables, glucosamine or chondroitin initiated less than 2 months prior to inclusion.
  • Patient with hypersensitivity to hyaluronic acid or tranexamic acid.
  • Patient with a history of seizures.
  • Patient who had arthroscopy of the target knee or major trauma to the target knee during the 3 months preceding inclusion.
  • Patient scheduled to undergo surgery, for any cause, of the target knee or other joint of the lower limbs, planned within 6 months of inclusion, likely to interfere with follow-up or evaluation of the patient in the study.
  • Patient with Fibromyalgia.
  • Patient with an active neurological or vascular musculoskeletal disorder (such as rheumatoid arthritis, lupus, psoriatic arthritis, spondyloarthritis or any other autoimmune disease, Paget's disease, gout, coxopathy, tendinopathy of the lower limb, sciatic or crural radiculalgia) that could interfere with the measurement of the effectiveness of the treatment of the knee evaluated.
  • Patient with hemostasis disorders, venous or lymphatic stenosis of the lower limbs, history of thromboembolic disease - phlebitis or pulmonary embolism - or a high risk of thromboembolism.
  • Patients with an evolving general cardiac, digestive, endocrine, haematological or broncho-pulmonary condition which, in the opinion of the investigator, would be likely to disrupt regular monitoring and/or interfere with the measurement of treatment efficacy .
  • Breastfeeding patient, pregnant or wishing to be during the 6 months of the study.
  • Patient unable to give personal consent.
  • Patient with renal insufficiency.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Medical Device : Happyone
Hyaluronic acid associated with tranexamic acid ; 4.8 ml will be injected in one time
Device: Intra-articular single injection

Both groups will receive their first injection after a selection visit ; first injection will be planned between 7 days to 30 days after to confirm the enrollment.

The injection will be performed at Day 1.
Experimental: Medical Device : Happysoft
Hyaluronic acid associated with tranexamic acid ; 2.2 ml will be injected in three times (one injection per week)
Device: Intra-articular three injections

Both groups will receive their first injection after a selection visit ; first injection will be planned between 7 days to 30 days after to confirm the enrollment.

The injections will be performed at Days 1, 8 and 15.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of adverse event attributable to the investigational Medical Device during the week following each injection.
Time Frame: 1 month

Adverse events will be collected at :

  • Day 8 for Happyone arm (single injection) ;
  • Days 8, 15 and 22 for Happysoft arm (three injections).
1 month

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of adverse events during the month following the first injection for immediate and delayed local tolerance evaluation.
Time Frame: 1 month

All adverse events will be collected at :

  • Days 3, 8, 22 and 29 for Happyone arm (single injection) ;
  • Days 3, 8, 10, 15, 17, 22 and 29 for Happysoft arm (three injections). Number of adverse events occurring beyond the week following each injection from Day 1 to D29.
1 month
Patient self-assesment of the overall tolerance of the treatment based on a 5-point scale, from "Very bad" to "Very good".
Time Frame: 1 month

This questionnaire will be completed at :

  • Days 3, 8, 22 and 29 for Happyone arm (single injection) ;
  • Days 3, 8, 10, 15, 17, 22 and 29 for Happysoft arm (three injections).
1 month
Variation over time of the WOMAC score, between time of injection and end point, and the WOMAC subscores A (pain) and C (function). The WOMAC-Questionnaire is based on a 11 points scale, from 0 = None to 10 = Extreme.
Time Frame: 6 months

This questionnaire will be completed at :

  • Day 1, Day 8, Month 1, Month 3 and Month 6 for Happyone arm (single injection) ;
  • Day 1, Day 8, Day 15, Month 1, Month 3 and Month 6 for Happysoft arm (three injections).
6 months
Patient self-assesment of the effectiveness of the treatment based on a 11 points numeric scale, from 0 = None to 10 = Total.
Time Frame: 6 months
This questionnaire will be completed at Months 1, 3 and 6 for both groups.
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Labrha

Collaborators

Statitec

Investigators

  • Principal Investigator: Jean-Charles Balblanc, MD, Hôpital Nord Franche-Comté, HNFC

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 8, 2022

Primary Completion (Actual)

January 18, 2023

Study Completion (Actual)

June 14, 2023

Study Registration Dates

First Submitted

June 2, 2022

First Submitted That Met QC Criteria

June 8, 2022

First Posted (Actual)

June 10, 2022

Study Record Updates

Last Update Posted (Actual)

June 22, 2023

Last Update Submitted That Met QC Criteria

June 20, 2023

Last Verified

June 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2021-A01153-38

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Knee Osteoarthritis

Clinical Trials on Intra-articular single injection

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ukraine

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe